HLA-DRB1: Genetic susceptibility and disability progression in a Spanish multiple sclerosis population

European Journal of Neurology

Volumn 18, Issue 2, 2011, Pages 337-342

  Romero Pinel, L ^a   Pujal, J M ^a   Martinez Yelamos S ^a   Gubieras, L ^a   Matas, E ^a   Bau, L ^a   Torrabadella, M ^b   Azqueta, C ^b   Arbizu, T ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b Banc de sang i teixits ^*  (Spain)

Author keywords

Alleles; Genetics; HLA DR; Multiple sclerosis; Phenotype; Prognosis

Indexed keywords

HLA DR ANTIGEN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

ADULT; ALLELES; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HLA-DR ANTIGENS; HUMANS; MALE; MULTIPLE SCLEROSIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; SPAIN;

EID: 77958154257     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2010.03148.x     Document Type: Article

References (57)

1. Ramagopalan SV, Ebers GC. Genes for multiple sclerosis. Lancet 2008; 371: 283-285.
2. Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol 2008; 7: 268-277.
3. Ramagopalan SV, Dyment DA, Ebers GC. Genetic epidemiology: the use of old and new tools for multiple sclerosis. Trends Neurosci 2008; 31: 645-652.
4. Ebers GC, Kukay K, Bulman DE, et al. A full genome search in multiple sclerosis. Nat Genet 1996; 13: 472-476.
5. Dyment DA, Ebers GC, Sadovnick AD. Genetics of multiple sclerosis. Lancet Neurol 2004; 3: 104-110.
6. Baranzini SE, Wang J, Gibson RA, et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet 2009; 18: 767-778.
7. Sawcer S. The complex genetics of multiple sclerosis: pitfalls and prospects. Brain 2008; 131: 3118-3131.
8. Hafler DA, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357: 851-862.
9. Hoppenbrouwers IA, Aulchenko YS, Ebers GC, et al. EVI5 is a risk gene for multiple sclerosis. Genes Immun 2008; 9: 334-337.
10. Aulchenko YS, Hoppenbrouwers IA, Ramagopalan SV, et al. Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis. Nat Genet 2008; 40: 1402-1403.
11. Ramagopalan SV, Knight JC, Ebers GC. Multiple sclerosis and the major histocompatibility complex. Curr Opin Neurobiol 2009; 22: 219-225.
12. Lincoln MR, Montpetit A, Cader MZ, et al. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat Genet 2005; 37: 1108-1112.
13. Schmidt H, Williamson D, Ashley-Koch A. HLA-DR15 haplotype and multiple sclerosis: a HuGE review. Am J Epidemiol 2007; 165: 1097-1109.
14. Dyment DA, Herrera BM, Cader MZ, et al. Complex interaction among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Hum Mol Genet 2005; 14: 2019-2026.
15. Ramagopalan SV, Morris AP, Dyment DA, et al. The inheritance of resistance alleles in multiple sclerosis. PLoS Genet 2007; 3: 1607-1613.
16. Lincoln MR, Ramagopalan SV, Chao MJ, et al. Epistasis among HLA-DRB1, HLA-DQA1, and HLA-DQB1 loci determines multiple sclerosis susceptibility. Proc Natl Acad Sci USA 2009; 106: 7542-7547.
17. Ramagopalan SV, Ebers GC. Epistasis: multiple sclerosis and the major histocompatibility complex. Neurology 2009; 72: 566-567.
18. DeLuca GC, Ramagopalan SV, Herrera BM, et al. An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proc Natl Acad Sci USA 2007; 104: 20896-20901.
19. Chao MJ, Bernardo MC, Lincoln MR, et al. HLA class I alleles tag HLA-DRB1*1501 haplotypes for differential risk in multiple sclerosis susceptibility. Proc Natl Acad Sci USA 2008; 105: 13069-13074.
20. Pina MA, Ara JR, Lasierra P, Larrad L, Modrego PJ. Major histocompatibility complex class II alleles and the course and outcome of MS. Neurology 1999; 52: 1923-1924.
21. Uría DF. HLA y esclerosis múltiple. Estudios en la población española. Rev Neurol 2000; 31: 1066-1070.
22. Villoslada P, Barcellos LF, Rio J, et al. The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-bet. J Neuroimmunol 2002; 130: 194-201.
23. Fernández O, Fernández V, Alonso A, et al. DQB1*0602 allele shows a strong association with multiple sclerosis in patients in Malaga, Spain. J Neurol 2004; 251: 440-444.
24. Fernández O, Fernández V, Martinez-Cabrera V, et al. Multiple sclerosis in gypsies from southern Spain: prevalence, mitochondrial DNA haplogroups and HLA class II association. Tissue Antigens 2008; 71: 426-433.
25. Fernández O, R-Antigüedad A, Pinto-Medel MJ, et al. HLA class II alleles in patients with multiple sclerosis in the Biscay province (Basque Country, Spain). J Neurol 2009; 256: 1977-1988.
26. Official statistics website of Catalonia. (accessed 25/03/2010).
27. Flores C, Maca-Meyer N, González AM, et al. Reduced genetic structure of the Iberian península revealed by Y-chromosome analysis: implications for population demography. Eur J Hum Genet 2004; 12: 855-863.
28. Ramagopalan SV, Deluca GC, Degenhardt A, Ebers GC. The genetics of clinical outcome in multiple sclerosis. J Neuroimmunol 2008; 202: 183-199.
29. Confavreux C, Compston DA, Hommes OR, McDonald WI, Thompson AJ. EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry 1992; 55: 671-676.
30. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
31. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005; 58: 840-846.
32. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-911.
33. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
34. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39: 225-235.
35. Payami H, Joe S, Farid NR, et al. Relative Predispositional Effects (RPEs) of marker alleles with disease: HLA-DR alleles and Graves disease. Am J Hum Genet 1989; 45: 541-546.
36. McDonnell GV, Mawhinney H, Graham CA, Hawkins SA, Middleton D. A study of the HLA-DR region in clinical subgroups of multiple sclerosis and its influence on prognosis. J Neurol Sci 1999; 165: 77-83.
37. Masterman T, Ligers A, Olsson T, Andersson M, Olerup O, Hillert J. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol 2000; 48: 211-219.
38. Ballerini C, Guerini FR, Rombolà G, et al. HLA-multiple sclerosis association in Continental Italy and correlation with disease prevalence in Europe. J Neuroimmunol 2004; 150: 178-185.
39. Brassat D, Salemi G, Barcellos LF, et al. The HLA locus and multiple sclerosis in Sicily. Neurology 2005; 64: 361-363.
40. Dean G, Yeo TW, Goris A, et al. HLA-DRB1 and multiple sclerosis in Malta. Neurology 2008; 70: 101-105.
41. Barcellos LF, Oksenberg JR, Green AJ, et al. Genetic basis for clinical expression in multiple sclerosis. Brain 2002; 125: 150-158.
42. Brum DG, Barreira AA, Louzada-Junior P, Mendes-Junior CT, Donadi EA. Association of the HLA-DRB1*15 allele group and the DRB1*1501 and DRB11*1503 alleles with multiple sclerosis in White and Mulatto samples from Brazil. J Neuroimmunol 2007; 189: 118-124.
43. Patrucco L, Larriba J, Redal MA, Rojas JI, Argibay PF, Cristiano E. HLA-DRB1 and multiple sclerosis in Argentina. Eur J Neurol 2009; 16: 427-429.
44. Stankovich J, Butzkueven H, Marriott M, et al. HLA-DRB1 associations with disease susceptibility and clinical course in Australians with multiple sclerosis. Tissue Antigens 2009; 74: 17-21.
45. De la Concha EG, Arroyo R, Crusius JBA, et al. Combined effect of HLA-DRB1*1501 and interleukin-1 receptor antagonist gene allele 2 in susceptibility to relapsing/remitting multiple sclerosis. J Neuroimmunol 1997; 80: 172-180.
46. Smestad C, Brynedal B, Jonasdottir G, et al. The impact of HLA-A and -DRB1 on age at onset, disease course and severity in Scandinavian multiple sclerosis patients. Eur J Neurol 2007; 14: 835-840.
47. Silva AM, Pereira C, Bettencourt A, et al. The role of HLA-DRB1 alleles on susceptibility and outcome of a Portuguese multiple sclerosis population. J Neurol Sci 2007; 258: 69-74.
48. Barcellos LF, Sawcer S, Ramsay PP, et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet 2006; 15: 2813-2824.
49. Romero-Pinel L, Martínez-Yélamos S, Gubieras L, et al. Anticipation of age at onset in familial multiple sclerosis. Eur J Neurol 2010; 17: 572-575.
50. Hensiek AE, Sawcer SJ, Feakes R, et al. HLA-DR15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J Neurol Neurosurg Psychiatry 2002; 72: 184-187.
51. Cree BA, Reich DE, Khan O, et al. Modification of multiple sclerosis phenotypes by African ancestry at HLA. Arch Neurol 2009; 66: 226-233.
52. Wu JS, Qiu W, Castley A, et al. Modifying effects of HLA-DRB1 allele interactions on age at onset of multiple sclerosis in Western Australia. Mult Scler 2010; 16: 15-20.
53. Weinshenker BG, Santrach P, Bissonet AS, et al. Major histocompatibility complex class II alleles and the course and outcome of MS: a population-based study. Neurology 1998; 51: 742-747.
54. Runmarker B, Martinsson T, Wahlström J, Andersen O. HLA and prognosis in multiple sclerosis. J Neurol 1994; 241: 385-390.
55. Vasconcelos CC, Fernández O, Leyva L, Thuler LC, Alvarenga RM. Does the DRB1*1501 allele confer more severe and faster progression in primary progressive multiple sclerosis patients? HLA in primary progressive multiple sclerosis J Neuroimmunol 2009; 214: 101-103.
56. Cournu-Rebeix I, Génin E, Leray E, et al. HLA-DRB1*15 allele influences the later course of relapsing remitting multiple sclerosis. Genes Immun 2008; 9: 570-574.
57. Wu JS, James I, Qiu W, et al. HLA-DRB1 allele heterogeneity influences multiple sclerosis severity as well as risk in Western Australia. J Neuroimmunol 2010; 219: 109-113.